SUMMARY In a randomised controlled trial recombinant interferon alpha 2A (Roferon-A, rIFN alfa A) given at a dosage of 10 million units (MU)/m2 thrice weekly for six months was significantly better (p<002) than no treatment in producing a sustained loss of hepatitis Be antigen (HBeAg) in hepatitis B virus (HBV) chronic carriers. Although lower doses (5 MU/M2 and 2-5 MU/M2) also produced some responses, the seroconversion rate was not significantly greater than that observed in the control group. Sixteen of the 45 patients receiving interferon were human immunodeficiency virus (HIV) antibody positive: none of these responded. Forty one per cent of the anti-HIV negative patients receiving interferon (12/29, p<O005) lost HBeAg and 17% (5/29) lost hepatitis B surface antigen (HBsAg). The response rate among these anti-HIV negative patients receiving at least three months therapy was 46% and 19% respectively. Low pretreatment HBV-DNA and absence of anti-HIV were the only significant independent variables predicting response to therapy (p<003 and p<0 05 respectively). In six patients, neutralising antibodies to alpha interferon were detected during therapy, the majority being non-responders.
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Both adenine arabinoside monophosphate (Ara-AMP) and the alpha interferons have been used successfully to treat chronic hepatitis B virus (HBV) infection.`'-Lymphoblastoid interferon, used on a thrice weekly basis for three months, has been shown to have equal or possibly greater effectiveness than Ara-AMP. Furthermore, lymphoblastoid interferon, in contrast to Ara-AMP, may result in clearance of HBs as well as HBeAg.3 More recently, when recombinant interferon with alfa 2A was used in both high5 and low6 dosages, it was shown to produce transient inhibition of viral replication.
The aims of the present study were, first to evaluate the effectiveness of rIFN alfa A in eradicating HBV and second to see if lower doses than have previously been used would be effective.
Methods

PATIENi S
Sixty adult male patients (58 Caucasian, two Chinese) who met the trial criteria were entered into the study (Table 1 ). All eligible patients gave informed consent and were randomised into four groups by opening numbered computer generated randomisation envelopes in sequential order; the control group received no treatment and the three treatment groups received rIFN alfa A at the doses of 2.5, 5.0, and 10 MU/mi thrice weekly for six months.
The patient characteristics are given in Table 2 .
Roferon-A therapy for chronic HBV The treated patients received thrice weekly intramuscular injections for six months as outpatients. The majority were taught to selfadminister the injection at night, which they found more convenient.
All trial participants were seen weekly for one month, then every fortnight for five months. After treatment was stopped they were seen at three monthly intervals for 12 months. A clinical evaluation, history of interferon side effects, full blood count, urea and electrolytes, a blood sugar level, prothrombin index, liver function tests, as well as hepatitis serology and an HBV-DNA level were performed on each visit.
All patients were requested to have a liver biopsy at the end of the trial. Pre-and post-treatment biopsies were compared by an experienced histopathologist without knowledge of the serological status and relationship to therapy. Figure 3 . Eight responders have developed antiHBe, and four of five losing HBsAg also developed anti-HBs. Fifteen patients did not experience a rapid fall in HBV-DNA after the initial gradual fall. In these patients the HBV-DNA level continued to be sup- pressed, maximally at the second month, then the level started to increase towards pretreatment values at the fifth and sixth months, despite continued interferon therapy (Fig. 4) . One patient lost both HBsAg and HBeAg after four months therapy but became HBsAg positive again at the end of treatment. He remained, however, HBeAg negative. Eighteen patients did not exhibit any changes in HBV-DNA while on rIFN alfa A. Ten of 18 of this group were also anti-HIV positive.
ANTI-INTERFERON ANTIBODIES
These were detected during therapy in six anti-HIV negative patients, four being treated with 10 MU/mi. Five of these patients were non-responders in whom antibodies were first detected at 1, 3, 4, 5, and 6 months respectively. One patient who responded by loss of HBsAg, HBeAg, and HBV-DNA at three months, developed anti-interferon antibodies at six months of therapy. In two non-responders, the HBV-DNA had initially fallen in response to therapy but rose again after the anti-interferon antibodies appeared (Fig. 5) . For Table 4 . More side effects were seen as the dose increased. The physical performance reduction from 100% to 80% (WHO classification) in the majority of those treated with 10 MU/m' meant that their ability to work was impaired resulting in much time off work.
A number of patients reported mood changes, irritability, and depression. This was worse towards the end of the treatment and was more marked at the higher doses. One anti-HIV positive patient Six patients (all anti-HIV positive) felt unable to tolerate more than three months' therapy because of depression. This occurred equally on 2-5, 5, or 10 MU/m2 doses. Therapy was discontinued in the HIV associated thrombocytopenic patient after three months. One patient withdrew after two months therapy when he acquired syphilis which was treated elsewhere.
Eight patients required a dose reduction in the last two to three months of therapy. Three were on 5 MU/ m2 dose (two because of fatigue and one because of irritability and depression). Five were on the 10 MU/Mr dose, four because of extreme fatigue (irritability and difficulty concentrating in two) and one because of a drug induced granulocytopenia (which reversed on reducing the dose).
Symptomatic and haematological side effects reversed within a week of stopping therapy, whilst decreased hair growth took up to six months to recover.
Discussion
Recombinant alpha interferon used thrice weekly for six months, has been found to be a safe and effective treatment for chronic HBV infection in these predominantly homosexual HBV carriers. Overall there was a 27% response rate (loss of HBeAg and HBV-DNA), which is significantly higher than that observed in our control group and higher than the 5-10% predicted annual seroconversion rate quoted in the literature for this group of patients."L All treatment responders were anti-HIV negative giving a response rate of 41% in this group. For patients who tolerated a minimum of three months therapy the response rate was 29% overall and 44%o in anti-HIV negative individuals respectively. In addition 41% of the responders lost HBsAg over the six month treatment period, which is much higher than the observed loss in our control group and that expected from the literature.'4 Although responses were seen with 2-5 and 5.0 MU/mr dose regimens, the best results were obtained with 10 MU/mr' thrice weekly for six months. There are certain theoretical reasons why alpha interferon may be effective in chronic HBV carriers.
A number of authors have shown in i'itro" "' and in viVo'7 defects in alpha interferon production in chronic HBV carriers, and the administration of alpha interferon may correct these defects. We have shown both in this and a previous trial' that alpha interferon is effective in homosexual HBV carriers, whereas Ara-AMP is not.'`This may relate to the immunostimulatory properties of interferon. Immunological abnormalities have been shown in homosexual men in the absence of anti-HIV. 19-2' The detection of anti-interferon antibodies in a small minority of the treated patients was none the less significant as the majority of these were nonresponders. Other workers have shown that such antibodies can significantly reduce the response to treatment of patients with chronic myeloid leukaemia'' and hairy cell leukaemia.' The appear-ance of these antibodies became significant mainly after six months of therapy. These results suggest that the response may be prevented in a small number of patients during early therapy, especially as the HBV-DNA was seen to rise after antibody detection in two patients.
The Hepatitis B is an immunopathic virus against which a competent cell mediated response to HBcAg and HBeAg is required if the virus is to be eliminated.3" There have also been reports of HBV-DNA sequences in the lymphocytes of AIDS patients, regardless of HBV serology"" and it is possible that HBV replication in lymphocytes may impair their immune responsiveness. The lack of effect of rIFN alfa A in anti-HIV positive carriers is not confined to hepatitis B, however, as these patients also appear to be resistant to its effects when used intralesionally for the treatment of anal warts. ' We found that 41% of our responders lost HBsAg as well as HBeAg, and it is our preliminary observation that those treated early on in the course of their chronic HBV infection are more likely to completely eradicate the virus."" Ten of 12 of our responders had cleared HBV-DNA after three months of therapy. In a previous trial from this centre comparing the effectiveness of three and six months of lymphoblastoid interferon, the six months' therapy did not show any advantage over the three months' course, and our present results appear to confirm this.
Other investigators have found that high pretreatment AST values and chronic active hepatitis on liver biopsy to be important independent variables in predicting a favourable outcome of treatment.I" 32 The only predictive factor we found was a low pretreatment HBV-DNA level and negative anti-HIV status. It is noteworthy that these patients have lower AST and higher HBV-DNA values than patients in previous trials from this centre'-most likely reflecting the higher proportion of homosexuals and anti-HIV positive patients present in this study. We conclude that recombinant alpha interferon is an effective and well tolerated form of therapy for the management of chronic HBV infection in some anti-HIV negative carriers. Chronic HBV carriers who are anti-HIV positive tolerate treatment less well and may need some additional immune modulation to increase their likelihood of response.
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